Calyptus Wins FDA Approval for Bovana Generic

Calyptus Pharmaceuticals has secured FDA approval for its generic version of Sunovion Pharmaceuticals’ Brovana (arformoterol tartrate inhalation solution) as a maintenance treatment for bronchoconstriction in patients with obstructive pulmonary disease (COPD).

Calyptus, which co-developed the drug with VistaPharm, noted that the long-term, twice daily inhalation therapy may be used by patients with chronic bronchitis and emphysema.

U.S. sales of arformoterol tartrate inhalation solution, reached an estimated $104 million for the 12-month period ending June 2022, according to the healthcare analytics firm IQVIA.